Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study…
Popularity: unranked [?]
Related posts:
- Naurex Inc. Initiates Phase I Clinical Trial Of Its Novel Mechanism NMDA Modulator GLYX-13 In Treatment-Resistant Depression
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety
Comments
No Responses to “Naurex Inc. Initiates Phase I Clinical Trial Of Its Novel Mechanism NMDA Modulator GLYX-13 In Treatment-Resistant Depression”